➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Johnson and Johnson
Harvard Business School
Moodys
AstraZeneca

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BACILLUS CALMETTE-GUERIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for bacillus calmette-guerin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003129 Chemotherapy in Treating Patients With Early-Stage Bladder Cancer Completed National Cancer Institute (NCI) Phase 2 1998-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage bladder cancer that has not responded to BCG therapy.
NCT00003129 Chemotherapy in Treating Patients With Early-Stage Bladder Cancer Completed Eastern Cooperative Oncology Group Phase 2 1998-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage bladder cancer that has not responded to BCG therapy.
NCT00234039 S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin Completed National Cancer Institute (NCI) Phase 2 2006-11-01 RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine directly into the bladder may kill more tumor cells. PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with recurrent bladder cancer that has progressed despite previous Bacillus Calmette-Guerin (BCG).
NCT00234039 S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin Completed Southwest Oncology Group Phase 2 2006-11-01 RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine directly into the bladder may kill more tumor cells. PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with recurrent bladder cancer that has progressed despite previous Bacillus Calmette-Guerin (BCG).
NCT00384891 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated Medical Enterprises Europe B.V. Phase 3 2002-02-01 The study is designed to compare the efficacy and safety of 2 treatment types for the prevention of tumor recurrence of superficial bladder cancer: 1. A combination of bladder wall heating and local chemotherapy (Synergo) 2. Bacillus Calmette-Guérin (BCG)
NCT00396370 BCG Vaccination Delivered Intradermally, Orally and by Combined Routes Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2008-12-01 This study will assess the safety of a Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) and will evaluate if giving the vaccine by mouth, injection, or by both methods produces greater results. BCG vaccine and/or placebo (substance containing no medication) will be given by mouth and/or by injection into the skin. This study, conducted at Saint Louis University, will enroll 60 (up to 80) healthy volunteers, 18-40 years old, who are negative for a TB test (QuantiFERON®-Gold) and human immunodeficiency virus (HIV). Study procedures will include a physical exam; review of TB exposure history and medical history; collection of multiple samples of blood, urine, stool, tears, and nose fluid; and skin and blood tests for TB. Volunteers may participate for about 24 months.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for bacillus calmette-guerin

Condition Name

Condition Name for bacillus calmette-guerin
Intervention Trials
Bladder Cancer 32
Urinary Bladder Neoplasms 6
Non-muscle Invasive Bladder Cancer 4
Bladder Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for bacillus calmette-guerin
Intervention Trials
Urinary Bladder Neoplasms 52
Carcinoma 9
Carcinoma, Transitional Cell 8
Carcinoma in Situ 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for bacillus calmette-guerin

Trials by Country

Trials by Country for bacillus calmette-guerin
Location Trials
United States 130
Canada 12
Netherlands 8
Australia 7
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for bacillus calmette-guerin
Location Trials
Maryland 9
Texas 9
California 8
New York 8
Pennsylvania 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for bacillus calmette-guerin

Clinical Trial Phase

Clinical Trial Phase for bacillus calmette-guerin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for bacillus calmette-guerin
Clinical Trial Phase Trials
Not yet recruiting 23
Completed 18
Recruiting 13
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for bacillus calmette-guerin

Sponsor Name

Sponsor Name for bacillus calmette-guerin
Sponsor Trials
National Cancer Institute (NCI) 5
The University of Texas Health Science Center at San Antonio 3
Mansoura University 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for bacillus calmette-guerin
Sponsor Trials
Other 73
Industry 33
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Express Scripts
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.